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Redesigning the AIDS response for long-term impact
Heidi J Larson,a Stefano Bertozzib & Peter Piota
Why aids2031?
Despite signs of progress, the world is far from beating the 
acquired immunodeficiency syndrome (AIDS).1 In 2009 alone 
there were an estimated 2.6 million new human immunodefi-
ciency virus (HIV) infections and 1.8 million deaths globally.2 
In 2009, 69% of the world’s new HIV infections and 72% of the 
deaths were in sub-Saharan Africa, where average life expec-
tancy in several countries has decreased by 20 years or more 
since 1990.2 In these hyperendemic countries in sub-Saharan 
Africa, AIDS has had a significant adverse effect on maternal 
mortality rates3 and is still the first cause of death overall.
Recognizing the need for a shift in the AIDS response 
from “crisis management to sustained strategic response”,4 the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) 
established an independent forum called aids2031, engaging 
scientists, policy-makers, programme managers and activists 
to take a long-term view on the direction of the epidemic and 
to consider what is needed to achieve better outcomes by 2031, 
the year that will mark 50 years since AIDS was first recog-
nized.5 The recent global financial crisis has also added urgency 
as resources for competing global problems become tighter.
Between 2007 and 2010, the aids2031 consortium con-
vened working groups that focused on nine areas: social drivers 
of the epidemic, epidemiological and economic modelling, 
science and technology, the programmatic response, com-
munications, leadership, financing, hyperendemic countries 
in sub-Saharan Africa, and countries in rapid economic 
transition in Asia. The working group participants, selected 
from a variety of disciplines and geographical areas, along 
with a group of young leaders, together engaged more than 
500 people around the world to bring new ideas to address a 
pandemic that is still growing despite great investment and 
efforts to control it. The consortium’s mandate was to ask what 
needs to be done better or differently now to radically reduce 
the number of new HIV infections and AIDS deaths by 2031.
The working groups consultations have resulted in inter-
national forums and debates, more than 30 working papers, 
reports6,7 and a book7capturing key findings and recommenda-
tions. The aids2031 analyses assume a changing global context 
with many uncertainties – in politics, the environment, eco-
nomics, technology and overall health and development. By 
2031, changes will likely include a further shift in the global 
geopolitical and economic centre to Asia, especially China 
and India; unpredicted social changes; important advances in 
information technologies;8 different models of development 
aid and global health funding; climate change;9 and an already 
emerging dramatic shift in the global disease burden to higher 
rates of chronic diseases,10 alongside persisting old and pos-
sibly new infectious diseases. By 2030, the world’s population 
is expected to reach 8.3 billion people.11
Several recent events have changed the AIDS landscape. 
On the research side, there have been positive breakthroughs 
in demonstrating the effectiveness of treatment as prevention12 
as well as for oral and topical pre-exposure prophylaxis.13–15 
On the political side, the June 2011 United Nations’ Security 
Council Resolution on HIV/AIDS16 and General Assembly 
Political Declaration on HIV/AIDS17 reflect renewed political 
engagement and a changed strategy that focuses on highest 
risk populations, even though this may be more politically 
sensitive.18
The first three decades
The AIDS epidemic has evolved in a unique way.19 First, there 
were rapid scientific breakthroughs. However, early over-opti-
mistic statements encouraged the public to believe that medical 
science could develop a vaccine in a much shorter time-frame 
than has been feasible. The difficulty of changing sexual and 
drug-using behaviours was also greatly underestimated.
Second, the AIDS epidemic engaged an exceptional co-
alition of scientists, activists and policy-makers that helped 
mobilize funds. International funds for low- and middle-
income countries grew from 292 million United States dollars 
(US$) in 1996 to US$ 15.9 billion by 2009.20 For the first time, 
global AIDS funding decreased in 2010. AIDS was the first 
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infectious disease to which the response 
was driven by human rights concerns, 
and one of its greatest hallmarks has 
been the engagement and activism of 
people living with HIV.
A third unprecedented aspect of the 
AIDS response was that it was the first 
time that high-income countries com-
mitted to fund treatment for a chronic 
illness in low- and middle-income coun-
tries. Mechanisms for sustained support 
for long-term treatment, though, were 
not adequately considered.
Finally, sensitivities around sex, 
sexual orientation and drug use have 
posed significant obstacles. Politics, 
religion, culture and societal stigma 
and discrimination have hampered the 
effective use of available interventions.21 
Preventing HIV transmission among 
injecting drug users has perhaps been 
the most neglected of interventions, 
particularly in eastern Europe, which is 
now paying a high price for that neglect.
Projections from the aids2031 Mod-
elling Working Group suggest that, even 
with highly intensified efforts, there will 
probably still be at least one million new 
annual HIV infections in 2031. With 
continued efforts at today’s current lev-
els, the numbers will be much higher.7
Redesigning the response
The aids2031 analyses recognize that 
there are several uncertainties around 
the evolution and spread of the virus 
and the development of drug resistance 
– and how these will be affected by social 
or political change. The most important 
breakthrough would be the discovery of 
an effective vaccine or a cure. Without 
either of these we will probably not be 
able to eliminate AIDS, but it should be 
possible to reduce new infections with 
wider availability of antiretroviral treat-
ment (ART) and new tools such as pre-
exposure prophylaxis and microbicides.
Key elements for a redesigned 
strategy include: (i) a new culture of 
knowledge generation and utiliza-
tion; (ii) transformed prevention and 
treatment to increase effectiveness; 
(iii) increased efficiency through better 
management and maximizing synergies 
with other programmes; and (iv) invest-
ment for the long term.
Culture of knowledge
A more knowledge-driven approach to 
AIDS is a central tenet of a long-term 
approach – which includes investment 
in gathering social, demographic, epi-
demiological and political information 
at the local level. This will allow better 
targeting of resources and will improve 
outcomes in the long term.
Systematic evaluation
Although there is already evidence of 
a growing emphasis on implementa-
tion and operational research in major 
programmes such as the United States 
President’s Emergency Plan for AIDS 
Relief (PEPFAR) and the Global Fund 
to Fight AIDS, Tuberculosis and Ma-
laria, prevention tools continue to be 
implemented without evaluating their 
effectiveness in different settings. This 
inefficiency allows poor quality pro-
grammes to continue while the best 
ones are not emulated. Continuous 
systematic programme monitoring and 
evaluation with prompt analysis and 
feedback are needed.22
Research and development
We are still in great need of new tools 
and knowledge, particularly for preven-
tion of HIV infection. The search for 
a vaccine, microbicide, pre-exposure 
prophylaxis or cure should be based on 
a long-term vision and be conducted in a 
more coordinated and strategic way.23,24 
Vaccine research would greatly benefit 
from a mission-driven approach in ad-
dition to investigator-initiated research. 
Closer integration of clinical trials and 
basic research, evaluation of combina-
tions of prevention interventions, and 
funding global multi-disciplinary con-
sortia in this field should be a priority.
Better diagnostics, including for 
tuberculosis, are also needed. One of the 
key recommendations of the aids2031 
Science and Technology Working Group 
is a global initiative to develop and de-
liver better diagnostic (e.g. tests for viral 
load) and monitoring tools (in particu-
lar an assay to measure HIV incidence) 
for use in low-income countries.25,26
Prevention and treatment
After successive waves of emphasizing 
either prevention or treatment, it is 
clear that an effective AIDS response 
must be based on both, particularly now 
that it has been demonstrated that ART 
reduces the rate of HIV transmission.13
Combination prevention
There are three key dimensions to trans-
forming prevention: (i) to create incen-
tives and stimulate demand for preven-
tion, (ii) to customize combinations of 
prevention interventions for maximum 
effectiveness for local settings, and 
(iii) to measure incidence of HIV in-
fection to evaluate programmes. Rede-
signing the AIDS prevention response 
means moving from a predominantly 
global approach to one that applies 
global learning to highly heterogeneous 
local epidemics. This includes tracking 
the local epidemiological profile, as well 
as understanding the social, cultural, 
economic and political context.27 Short-
sighted approaches that do not invest 
adequately in such local analyses and 
mathematical modelling will result in 
less efficiency and impact and greater 
long-term costs.
There is no “silver bullet” for pre-
vention. A combination of prevention 
approaches (e.g. partner limitation, 
condoms, male circumcision, couples 
HIV testing, antiretroviral treatment 
and harm reduction)28 should be tailored 
to each setting, and new tools adopted 
(e.g. pre-exposure prophylaxis) in the 
most strategic and cost-effective ways. 
Monitoring and evaluation can help 
guide the development of prevention 
packages for each community.29 Strong 
leadership is also needed to overcome 
political obstacles to using proven 
prevention approaches such as harm 
reduction. The notion of “know your 
epidemic, act on its politics” is crucial.17
Finally, we should be explicit that 
“universal access for HIV prevention” 
is not appropriate in every setting. 
Instead, the most effective prevention 
interventions should be targeted where 
they are most needed, recognizing that 
some settings will require significantly 
more investment of certain interven-
tions than others.
Optimize treatment
Current treatment approaches require a 
critical review to ensure that they save 
the most lives with available resources. 
There are more ongoing systematic 
efforts to improve the effectiveness 
and quality of ART than there are for 
HIV prevention.30 These include: more 
cost-effective therapeutic choices, such 
as fixed-dose combinations and opti-
mization of first-line regimens; more 
effective adherence strategies; improv-
ing the feasibility and reducing costs of 
delivery through task shifting – such as 
using non-physician health workers to 
assess patients’ eligibility for ART, start-
ing patients on ART and monitoring 
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outcomes;31 using community workers 
to improve adherence;32 and lowering 
the costs of laboratory monitoring.33 In 
this regard, the “Treatment 2.0” concept 
(by UNAIDS) which advocates for better 
treatment regimens, cheaper and sim-
pler diagnostic tools, and community-
led approaches to delivery is a timely 
initiative.34
Address the drivers
Epidemiological and qualitative research 
has shown that human rights, gender issues 
and economic factors do have an influence 
on the spread of HIV. However, there is 
little empirical evidence that structural in-
terventions can actually reduce HIV trans-
mission and so more research is needed.35
One of the key recommendations 
of the aids2031 Social Drivers Working 
Group is that “there is a package of reforms 
that constitute a minimum legal standard 
for facilitating an enabling environment 
for AIDS resilience”.36 These include the 
decriminalization of: HIV status, transmis-
sion and exposure; same-sex relationships/
sexual practices; and harm-reduction ap-
proaches for prevention of AIDS among 
injecting drug users.37 These measures are 
not just human rights imperatives; they 
create an environment to allow effective 
implementation of programmes and are 
an integral part of the AIDS agenda.
Increase efficiency
The current financial crisis is a major 
incentive to optimize the use of existing 
funds.38 Maximizing synergies with other 
health programmes and strengthening 
health services are key strategies to in-
creasing efficiency and have become cri-
teria for programmes supported by both 
PEPFAR and the Global Fund to Fight 
AIDS, Tuberculosis and Malaria.39,40
Good management practices
The efficiency of AIDS programmes can 
be greatly increased by adopting sound 
management practices, in particular 
management information systems that 
provide prompt feedback on perfor-
mance at the local implementation level. 
User-friendly, real-time monitoring 
systems are already available for social 
marketing and community-based pro-
grammes and can be adapted to moni-
tor other prevention activities, as the 
Avahan project did in India.41
Learn from the private sector
HIV prevention programmes have 
largely been based on behaviour change 
theories that have been of limited 
use in designing effective, large-scale 
programmes. Pragmatic business-like 
marketing and consumer influencing 
approaches are needed that continuously 
improve the “product” (i.e. prevention 
tools) and generate demand (marketing) 
so as to maximize “returns” (infections 
prevented).42
Integrate services intelligently
Given the early reluctance and lack of ex-
perience of the public health and medical 
establishment to deal with AIDS, separa-
tion of AIDS programmes from general 
health services and social programmes 
was justified in the beginning. However, 
it is now essential to move rapidly to intel-
ligent integration. Where HIV/tubercu-
losis co-infection is common, clinics that 
treat HIV should be “tuberculosis-com-
petent” and vice versa; ART provision 
can be seamlessly integrated into primary 
care in high-prevalence settings; and pre-
vention of mother-to-child transmission 
can become part and parcel of maternal, 
neonatal and child services – as exempli-
fied in the recent PEPFAR support to a 
global plan to eliminate mother-to-child 
HIV transmission.43 Community-based 
services and government services can 
work in a continuum; in many of the best 
HIV clinics, community-based organiza-
tions work alongside government provid-
ers, supporting treatment adherence and 
other services.
Invest for the long term
Asking whether today’s efforts are sus-
tainable obscures the reality that existing 
efforts and resources are insufficient to 
bring AIDS under control in low- and 
middle-income countries. With popula-
tion growth the world is generating the 
largest cohort of sexually active people 
in history, thus expanding the number of 
individuals susceptible to HIV infection. 
Access to treatment has significantly 
increased over the past decade, with 
more than 6 million people now on 
ART. But, what are the long-term plans 
to sustain the growing demand for treat-
ment? A recent paper by Schwärtlander 
et al. outlines a proposed investment 
approach for an effective HIV/AIDS 
response towards 2020 and makes it 
clear that significantly more resources 
will be needed.38
Multiyear funding
The importance of long-term funding is 
evident, yet short-term funding cycles 
persist, mostly because of fiscal impera-
tives. One- or two-year funding cycles 
do not allow an adequate time frame for 
testing the long-term impact of struc-
tural approaches. Short-term goals may 
motivate programmes to initiate patients 
on treatment, for example, but fall short 
of serving the longer term goals of en-
suring quality, adherence and sustained 
effective treatment. Even if planning is 
done for 5 years, it needs to be done 
with a horizon of at least 10–15 years 
so that programmes can make invest-
ments – such as in capacity building, in 
changing social norms or in addressing 
structural barriers to prevention – that 
will bear fruit beyond the current fund-
ing or planning cycle.
Performance indicators
Since performance targets and indica-
tors often drive programme content, 
it is vital that they reflect the need for 
long-term outcomes. For example, when 
evaluating ART, counting the number 
of people who initiate treatment should 
be modified to focus on the durability 
of therapy, especially on lower-cost, 
first-line therapy. When evaluating pre-
vention, reducing the incidence of HIV 
infection should be the key indicator; 
it is not sufficient to demonstrate the 
delivery of services.
Capacity building
Although most AIDS programmes 
contain a capacity building element, 
it is often limited to retraining medi-
cal personnel and is generally poorly 
funded. Many national AIDS pro-
grammes, particularly in Africa, still 
rely heavily on expensive consultants 
and intermediaries from high-income 
countries. While this can accelerate 
programme implementation, it may also 
create dependency, lack of local owner-
ship and even undermine local capacity. 
Long-term success requires sustained 
investment in building the local cadre 
of senior medical and management per-
sonnel. AIDS funding should therefore 
be made conditional on investments in 
local capacity building and the use of 
local institutions.
Finally, the engagement of people 
living with HIV has been one of the 
most important achievements in the 
AIDS response. However, meaningful 
involvement in decision-making and 
resource allocation by affected com-
munities is still not the norm.30 Specific 
opportunities for engaging people liv-
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ing with HIV must be created, par-
ticularly for prevention programmes. 
Evaluations should be conducted to 
determine the increased effectiveness 
of prevention workers who are also 
living with HIV.
An extraordinary approach 
in Africa
The elements of a long-term response to 
AIDS are relevant for all societies, but 
are probably insufficient to bring the 
epidemic in sub-Saharan Africa under 
control. The aids2031 Working Group 
on Hyperendemic Countries stressed 
that nothing less than extraordinary 
and sustained society-wide action will 
reduce the AIDS-related devastation 
sufficiently to enable these countries to 
devote adequate attention and resources 
to other pressing development concerns. 
A recent report, by the Institute of 
Medicine on AIDS in Africa towards 
2020, recommended 10-year country 
roadmaps, more efficient models of care 
and treatment, the integration of AIDS 
interventions with other relevant health 
programmes, and an analysis and long-
term plan to meet workforce needs.44
An exceptional AIDS response in 
sub-Saharan Africa is needed urgently, 
as confirmed by the June 2011 United 
Nations Political Declaration on HIV/
AIDS. Ideally, an intensified response 
would include:
i) A comprehensive prevention effort 
led from the highest levels of govern-
ment, the media and society maxi-
mizing demand, supply and quality 
of proven HIV prevention interven-
tions such as condoms, male cir-
cumcision, couple counselling and 
testing, provision of antiretroviral 
therapy and prevention of mother-
to-child transmission. Particular at-
tention to gender issues is crucial, as 
sub-Saharan Africa has the highest 
prevalence of HIV infection among 
young women. Better understanding 
is also needed on how to reach men 
who have sex with men and injecting 
drug users who are just starting to be 
acknowledged in Africa.
ii) Every adult citizen should know his 
or her HIV status and be supported 
and treated if infected with HIV. Dif-
ferent prevention services should 
be provided for those who are HIV-
negative and HIV-positive, with a 
special focus on those at higher risk 
of becoming infected or transmit-
ting HIV.
iii) Bold efforts, led by government 
where possible, to change social 
norms regarding gender inequality, 
sexual violence, age disparity among 
couples, and concurrent partner-
ships.
iv) A targeted, tailored strategy for pre-
vention and treatment is also needed 
for migrant labour, an urgent issue 
highlighted by the aids2031 Working 
Group on Hyperendemic Countries.
A road map of tough choices
One of the biggest challenges will be 
how to deal with competing issues for 
political attention, funding and deliv-
ery capacity. While there has been a 
remarkable mobilization of resources for 
AIDS in the past decade, new compet-
ing health and development priorities, 
the economic crisis and AIDS “fatigue” 
present new challenges that will need 
innovative funding strategies and 
mechanisms to meet the growing needs.
Efficiencies in spending are a mat-
ter of urgency, not only for AIDS pro-
grammes but for other development 
activities. Identifying areas of potential 
convergence (such as with maternal and 
child health and prevention of mother-
to-child transmission, and primary 
care services for ART) will not only be 
a cost-saving measure, but may help 
address other problems, such as work-
force shortages, while contributing to 
strengthening health systems.
Every society will have to address 
its own barriers to an effective AIDS 
response and make some tough choices. 
The aids2031 consortium has identified 
some key measures to consider:
•	 Leaders, societies and religious enti-
ties need to come to terms with the 
realities of sexuality and the impli-
cations for HIV transmission, and 
stand up for proven policies and 
interventions, despite their political 
unpopularity. Harm reduction mea-
sures for injecting drug users are par-
ticularly important.
•	 All countries should adopt a pack-
age of minimum legal standards as 
outlined earlier in this paper and dis-
cussed in the report of the aids2031 
Social Drivers Working Group.30
•	 AIDS funding should no longer sup-
port interventions of marginal ben-
efit (e.g. universal access for preven-
tion for people at lowest risk, control 
of sexually-transmitted infections 
for HIV prevention, or universal hy-
giene precautions for broader infec-
tion control, with the exception of 
safe blood and injections) until the 
most effective interventions are fully 
scaled-up for the populations most 
at risk.45
•	 International funding should be pri-
oritized for low-income and highly-
affected middle-income countries.
•	 A mission-driven, coordinated ap-
proach to vaccine and other research 
with better sharing of data is critical.
•	 Each country, international agency, 
research funder and nongovern-
mental organization should urgently 
review its AIDS strategy and pro-
grammes to ensure that they are de-
signed to maximize the reduction of 
HIV-related morbidity and mortality 
over the long term.
AIDS is not an equally important 
issue everywhere and there is no “one 
size fits all” solution to the epidemic. 
Governance and leadership on AIDS 
must adapt to the setting – some places 
need stronger leadership while others 
may need to reposition AIDS in the 
light of other more pressing priorities. 
However, in high-prevalence countries, 
AIDS must be a central societal issue, 
requiring both emergency and long-
term strategies. AIDS will remain a 
generations-long challenge. Its response 
demands a fundamental redesign to 
truly halt the epidemic. There are no 
short-term solutions. ■
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صخللما
دملأا ليوط يرثأتلا ثيح نم زديلإل يدصتلا ميمصت ةداعإ
 ،يشربلا  يعانلما  زوعلا  سويرف فاشتكا  ذنم  دوقع ةثلاث  تضقنا
 ،لماعلا  لوح  عقت  ةعونتم  ةئبوأ  لىإ  زديلإا  ةحئاج  تروطت  دقو
 كانه نأ عمو .ناكسلا نم يرثكلا ينب ًانطوتم سويرفلا اذه حبصأو
 غلب ثيح ،جلاعلا لىع لوصلحا قاطن عيسوت لامج في ًابيط ًامدقت
 تاسويرفلا  تاداضمب  ةلجاعم  لىع  اولصح  نلم  يريدقتلا  ددعلا
 دوهج  نأ  لاإ  ،2010  ماع  ةيانه  في  صخش  نويلم  6.6  ةيرقهقلا
 نويلم 2.6 تعقو ثيح ،يربك دح لىإ ةيفاك يرغ تلازام ةياقولا
 جلاعلا  لىع  بلطلا  ديازتي  مانيبو  .2009  ماع  في  ةديدج  ىودع
 سسأ ،2007 ماع فيو .هيرفوت ةطشنأ حنترتو ،ليومتلا ةردن دادزت
 ىمسي ًلاقتسم ىدتنم زديلإا ةحفاكلم كترشلما ةدحتلما مملأا جمانرب
 زديلإل  يلماعلا  يدصتلا  لىع  ةصحفتم  ةرظن  ءاقللإ  2031زديإ
 تلاامج  ةعبرأ  ةيملعلا  ةقرولا  هذه  ددتحو  .هسويرفب  ىودعلاو
 هذه  تاشاقن  لىإ  ًادانتسا  زديلإل  يدصتلا  طيطتخ  ةداعلإ  ةيسيئر
 لىولأا ةثلاثلا دوقعلا للاخ ةدافتسلما تابرلخاو سوردلاو ةردابلما
 ةدافتسلااو  فراعلما  ديلوتل  ةديدج  ةفاقث  دوجو  )1  :يهو  ءابولل
 )3  ؛ةيلاعفلا  ةدايز لجأ نم جلاعلاو ةياقولا  في لوحتلا  )2  ؛اهنم
 جمابرلا ينب رزآتلا ميظعتو ةرادلإا ينستح للاخ نم ةءافكلا ةدايز
 كانه تلااجلما هذه عيجم برعو .ليوط دملأ رماثتسلاا )4 ؛ىرخلأا
 تايولوأ  ديدتحو ،ةدايقلاو  ،ةيلحلما  تاردقلا  ءانب  لىع يوق ديكأت
.جمانبرلا تاينازيمو
摘要
重新设计具有长远影响的艾滋病应对
艾滋病病毒确认后的三十年来,艾滋病的大流行已经在世界
各地呈多样性蔓延。在很多人群中,艾滋病病毒已经流行。
尽管在扩大治疗获取方面已经取得很大进展,截至2010年
年底,估计已有660万人接受抗逆转录病毒疗法,但是预防
工作仍严重不足,仅2009年就有260万新增感染病例。治
疗需求在不断增大,而资金却越来越少,行动力也在逐渐减
弱。联合国艾滋病规划署(UNAIDS)于2007年发起了艾滋
病2031独立论坛,旨在以批判的观点看待全球艾滋病病毒/
艾滋病应对。基于此倡议的审议意见以及过去三十年里艾
滋病防治的经验教训,本文概述了重新设计艾滋病应对的四
个关键领域:(1)有关知识创新与运用的新文化;(2)转化预防
和治疗以提高有效性;(3)通过卓越管理、与其他计划协同
作用的最大化来提高效率;(4)长期投资。在所有这些领域,
地方能力建设、领导能力、优先考虑的实施项目和预算
都应给予高度重视。
Résumé
Repenser la riposte au sida pour un impact à long terme
Trente ans après l’identification du virus VIH, la pandémie du sida s’est 
développée en diverses épidémies dans le monde entier. Dans de 
nombreuses populations, le VIH est devenu endémique. Bien que des 
progrès satisfaisants aient été réalisés en matière d’élargissement de 
l’accès au traitement, avec 6,6 millions de personnes qui bénéficient 
d’une thérapie antirétrovirale fin 2010, les efforts de prévention sont 
encore très inadaptés puisque 2,6 millions de nouvelles infections 
ont été enregistrées en 2009. La demande de traitement augmente 
tandis que le financement se réduit et que le militantisme décline. 
En 2007, le Programme commun des Nations Unies sur le VIH/SIDA 
(ONUSIDA) a créé un forum indépendant, appelé aids2031, pour que 
celui-ci examine de manière critique la riposte mondiale au VIH/SIDA. 
Ce document présente quatre domaines clés pour une riposte au sida 
repensée, en se fondant sur les délibérations de cette initiative, ainsi 
que sur l’apprentissage et l’expérience des trois premières décennies 
de l’épidémie: (i) une nouvelle culture de génération et d’utilisation des 
connaissances, (ii) une transformation de la prévention et du traitement 
pour accroître l’efficacité, (iii) une amélioration de l’efficacité grâce à 
une meilleure gestion et à l’optimisation des synergies avec d’autres 
programmes, et (iv) un investissement à long terme. Dans tous ces 
domaines, un fort accent est mis sur le renforcement des capacités 
locales, le leadership, les priorités du programme et les budgets.
Trente ans après que l’identification du virus VIH, la pandémie du sida 
s’est développée en diverses épidémies dans le monde entier. Dans 
de nombreuses populations, le VIH est devenu endémique. Bien que 
des progrès satisfaisants soient réalisés en matière d’élargissement de 
l’accès au traitement, avec 6,6 millions de personnes qui bénéficient 
d’une thérapie antirétrovirale fin 2010, les efforts de prévention sont 
encore très inadaptés puisque 2,6 millions de nouvelles infections 
ont été enregistrées en 2009. La demande de traitement augmente 
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tandis que le financement se réduit et que le militantisme décline. 
En 2007, le Programme commun des Nations Unies sur le VIH/SIDA 
(ONUSIDA) a créé un forum indépendant, appelé aids2031, pour que 
celui-ci examine de manière critique la riposte mondiale au VIH/SIDA. 
Ce document présente quatre domaines clés pour une riposte au sida 
repensée, en se fondant sur les délibérations de cette initiative, ainsi 
que sur l’apprentissage et l’expérience des trois premières décennies 
de l’épidémie: (i) une nouvelle culture de génération et d’utilisation des 
connaissances, (ii) une transformation de la prévention et du traitement 
pour accroître l’efficacité, (iii) une amélioration de l’efficacité grâce à 
une meilleure gestion et à l’optimisation des synergies avec d’autres 
programmes, et (iv) un investissement à long terme. Dans tous ces 
domaines, un fort accent est mis sur le renforcement des capacités 
locales, le leadership, les priorités du programme et les budgets.
Резюме
Реструктуризация ответа на СПИД в расчете на долгосрочное воздействие
Спустя 30 лет после выявления вируса ВИЧ пандемия СПИДа 
превратилась в ряд разнообразных эпидемий в странах мира. 
ВИЧ стал эндемичным во многих группах населения. Несмотря на 
успехи в расширении доступа к лечению – по оценкам, в конце 
2010 года антиретровирусную терапию получали 6,6 млн чел., – 
усилия в области профилактики все еще недостаточны: в 2009 
году произошло 2,6 млн новых случаев заражения инфекцией. 
Спрос на лечение растет, в то время как финансирование 
становится все более скудным, а энтузиазм идет на убыль. В 2007 
году Совместная программа Организации Объединенных Наций 
по ВИЧ/СПИДу (ЮНЭЙДС) основала независимый форум aids2031 
с тем, чтобы критически оценить результаты ответа на ВИЧ/СПИД 
в мире. В статье определены четыре ключевые сферы, в которых 
должна происходить реструктуризация ответа на СПИД на основе 
анализа этой инициативы, а также знаний и опыта, приобретенных 
за первые 30 лет эпидемии: (i) новая культура накопления 
и использования знаний; (ii) преобразования в области 
профилактики и лечения в целях увеличения результативности; 
(iii) повышение экономической эффективности благодаря 
улучшению управления и максимизации синергетического 
эффекта от взаимодействия с другими программами; и 
(iv) долгосрочные инвестиции. Во всех этих сферах делается 
сильный акцент на формирование потенциала, лидерство, 
приоритетные цели программ и бюджеты на местном уровне.
Resumen
Desde que hace tres décadas se identificó el virus del VIH, la pandemia 
del SIDA se ha desarrollado en diversas epidemias a lo largo y ancho del 
mundo. En muchas poblaciones, el VIH se ha convertido en endémico. 
Mientras que el progreso en la expansión del acceso al tratamiento es 
bueno, se estima que 6,6 millones de personas seguían un tratamiento 
antirretroviral a finales del año 2010, los esfuerzos de prevención 
siguen siendo altamente inadecuados, con 2,6 millones de nuevas 
infecciones que se produjeron en 2009. La demanda de tratamiento está 
incrementando mientras que los fondos se han reducido y el activismo 
está disminuyendo. En 2007, el Programa Conjunto de las Naciones 
Unidas sobre el VIH/SIDA (ONUSIDA) estableció un foro independiente 
llamado aids2031 para observar críticamente la respuesta global al VIH/
SIDA. Este documento destaca las cuatro áreas clave para rediseñar 
una respuesta al SIDA en base a las deliberaciones de esta iniciativa y al 
aprendizaje y experiencia de las primeras tres décadas de la epidemia: 
(i) una nueva cultura de generación y utilización de conocimientos; (ii) 
prevención transformada y tratamiento para incrementar la eficacia; (iii) 
eficiencia incrementada mediante una mejor gestión y la maximización 
de las sinergias con otros programas; y (iv) inversión para el largo plazo. 
En todas estas áreas existe se enfatiza fuertemente la construcción de 
capacidad local, liderazgo, prioridades y presupuestos del programa.
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Corrigendum
In Volume 89, Number 10, October 2011, p. 708, the first sentence of the fifth 
paragraph should read: “The Planning Commission, the government agency 
responsible for the country’s Five-Year Plans, has pledged to spend more on 
health in the next plan, which begins next year.”
In volume 89, Number 10, October 2011, p. 749, the author line should have 
read: “Shaheen P Shah,a Clare E Gilbert,a Hessom Razavi,a Elizabeth L Turnerb & 
Robert J Lindfielda on behalf of the International Eye Research Network.”
